Interferon Gamma
- Generic Name
- Interferon Gamma
- Drug Type
- Biotech
- Unique Ingredient Identifier
- P050J5FWC5
- Background
Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. The interferon is primarily produced by activated T lymphocytes and natural killer cells.
- Associated Conditions
- Serious infections
A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma
- Conditions
- Melanoma
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 122
- Registration Number
- NCT00001296
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood
- Conditions
- Chronic Granulomatous Disease
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 100
- Registration Number
- NCT00001317
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma
- Conditions
- HealthyMycobacterium Infections, Atypical
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 60
- Registration Number
- NCT00001318
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections
- Conditions
- Mycobacterium Avium-Intracellulare Infection
- First Posted Date
- 2001-07-25
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 20
- Registration Number
- NCT00021567
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Interferon Gamma for Drug Resistant Tuberculosis
- Conditions
- PneumoniaPulmonary Tuberculosis
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 30
- Registration Number
- NCT00001407
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type I
- Conditions
- Leukocyte Adhesion Deficiency Syndrome
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 5
- Registration Number
- NCT00001905
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Phase III Randomized Study of Interferon Gamma in Children With Severe, Congenital Osteopetrosis
- Conditions
- Osteopetrosis
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- FDA Office of Orphan Products Development
- Target Recruit Count
- 30
- Registration Number
- NCT00004402
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.